{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T19:53:07Z","timestamp":1649015587442},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mod Rheumatol"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s10165-012-0722-x","type":"journal-article","created":{"date-parts":[[2012,7,25]],"date-time":"2012-07-25T17:56:45Z","timestamp":1343239005000},"page":"634-645","source":"Crossref","is-referenced-by-count":1,"title":["Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study"],"prefix":"10.1093","volume":"23","author":[{"given":"Tsukasa","family":"Matsubara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seizo","family":"Yamana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeto","family":"Tohma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirobumi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kohsaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Miyasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ami","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"722_CR1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nrd1989","volume":"5","author":"L Moreland","year":"2006","unstructured":"Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov. 2006;5:185\u20136.","journal-title":"Nat Rev Drug Discov"},{"key":"722_CR2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","volume":"344","author":"EH Choy","year":"2001","unstructured":"Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907\u201316.","journal-title":"N Engl J Med"},{"key":"722_CR3","volume-title":"Chronic rheumatic conditions","author":"World Health Organization","year":"2009","unstructured":"World Health Organization. Chronic rheumatic conditions. Geneva: World Health Organization; 2009."},{"key":"722_CR4","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/rheumatology\/36.8.884","volume":"36","author":"D Whalley","year":"1997","unstructured":"Whalley D, McKenna SP, De Jong Z, Van Der Heijde D. Quality of life in rheumatoid arthritis. Br J Rheumatol. 1997;36:884\u20138.","journal-title":"Br J Rheumatol"},{"key":"722_CR5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrd1109","volume":"2","author":"JS Smolen","year":"2003","unstructured":"Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov. 2003;2:473\u201388.","journal-title":"Nat Rev Drug Discov"},{"key":"722_CR6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","volume":"340","author":"ME Weinblatt","year":"1999","unstructured":"Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253\u20139.","journal-title":"N Engl J Med"},{"key":"722_CR7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthr Rheum. 2003;48:35\u201345.","journal-title":"Arthr Rheum"},{"key":"722_CR8","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594\u2013602.","journal-title":"N Engl J Med"},{"key":"722_CR9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/00002281-200205000-00002","volume":"14","author":"LG Criscione","year":"2002","unstructured":"Criscione LG, St Clair EW. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol. 2002;14:204\u201311.","journal-title":"Curr Opin Rheumatol"},{"key":"722_CR10","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932\u20139.","journal-title":"Lancet"},{"key":"722_CR11","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","volume":"349","author":"JM Kremer","year":"2003","unstructured":"Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349:1907\u201315.","journal-title":"N Engl J Med"},{"key":"722_CR12","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/rheumatology\/ken163","volume":"47","author":"JD Isaacs","year":"2008","unstructured":"Isaacs JD. Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future. Rheumatology (Oxford). 2008;47:1461\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"722_CR13","unstructured":"Close DR. Matrix metalloproteinase inhibitors in rheumatic diseases. Ann Rheum Dis. 2001;60(3):iii62\u201367."},{"key":"722_CR14","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.10294","volume":"46","author":"LW Moreland","year":"2002","unstructured":"Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthr Rheum. 2002;46:1470\u20139.","journal-title":"Arthr Rheum"},{"key":"722_CR15","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","volume":"144","author":"JM Kremer","year":"2006","unstructured":"Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud MC, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144:865\u201376.","journal-title":"Ann Intern Med"},{"key":"722_CR16","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114\u201323.","journal-title":"N Engl J Med"},{"key":"722_CR17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum. 1988;31:315\u201324.","journal-title":"Arthr Rheum"},{"key":"722_CR18","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.1780350502","volume":"35","author":"MC Hochberg","year":"1992","unstructured":"Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthr Rheum. 1992;35:498\u2013502.","journal-title":"Arthr Rheum"},{"key":"722_CR19","first-page":"2365","volume":"34","author":"HG Haggerty","year":"2007","unstructured":"Haggerty HG, Abbott MA, Reilly TP, DeVona DA, Gleason CR, Tay L, et al. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J Rheumatol. 2007;34:2365\u201373.","journal-title":"J Rheumatol"},{"key":"722_CR20","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthr Rheum. 1995;38:727\u201335.","journal-title":"Arthr Rheum"},{"key":"722_CR21","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/1529-0131(199809)41:9%3C1564::AID-ART6%3E3.0.CO;2-M","volume":"41","author":"DT Felson","year":"1998","unstructured":"Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthr Rheum. 1998;41:1564\u201370.","journal-title":"Arthr Rheum"},{"key":"722_CR22","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/aps.2009.13","volume":"30","author":"Y Ma","year":"2009","unstructured":"Ma Y, Lin BR, Lin B, Hou S, Qian WZ, Li J, et al. Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis. Acta Pharmacol Sin. 2009;30:364\u201371.","journal-title":"Acta Pharmacol Sin"},{"key":"722_CR23","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3899\/jrheum.080813","volume":"36","author":"R Westhovens","year":"2009","unstructured":"Westhovens R, Kremer JM, Moreland LW, Emery P, Russell AS, Li T, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol. 2009;36:736\u201342.","journal-title":"J Rheumatol"},{"key":"722_CR24","first-page":"3172","volume":"135","author":"LA Rubin","year":"1985","unstructured":"Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985;135:3172\u20137.","journal-title":"J Immunol"},{"key":"722_CR25","doi-asserted-by":"crossref","unstructured":"Houseman M, Potter C, Marshall N, Lakey R, Cawston T, Griffiths I, et al. Baseline serum MMP-3 levels in patients with rheumatoid arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8\u00a0years follow up. Arthr Res Ther. 2012;14:R30.","DOI":"10.1186\/ar3734"},{"issue":"Suppl","key":"722_CR26","first-page":"S32","volume":"19","author":"T Takeuchi","year":"2009","unstructured":"Takeuchi T, Abe T, Yamamoto A, Miyasaka N. New biologics for rheumatoid arthritis in Japan. A multi-center, randomized, double-blind, controlled, dose-response study of abatacept (BMS-188667) in Japanese active rheumatoid arthritis (RA) patients with an inadequate response to methotrexate [abstract]. Mod Rheumatol. 2009;19(Suppl):S32.","journal-title":"Mod Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10165-012-0722-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T16:25:44Z","timestamp":1646843144000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10165-012-0722-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,26]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["722"],"URL":"https:\/\/doi.org\/10.1007\/s10165-012-0722-x","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,26]]}}}